Conference Proceedings
Relationship of bone marrow blast (BMBL) response to overall survival (OS) in a multicenter study of rigosertib (Rigo) in patients (pts) with myelodysplastic syndrome (MDS) with excess blasts progressing on or after treatment with a hypomethylating agent (HMA)
Aref Al-Kali, Devendra Hiwase, Maria R Baer, Peter Greenberg, Jake Shortt, Robert Collins, David P Steensma, Amit Verma, Gail J Roboz, Jamile M Shammo, Oliver G Ottmann, John Francis Seymour, Jeffrey Szer, Wolfgang Meyer, Patrick Simon Zbyszewski, Michael E Petrone, Steven M Fruchtman, Guillermo Garcia-Manero, Lewis R Silverman
JOURNAL OF CLINICAL ONCOLOGY | AMER SOC CLINICAL ONCOLOGY | Published : 2017
Abstract
7056 Background: No therapies are approved for MDS after HMA failure. 04-24 was a single-arm study to evaluate best BMBL response as a potential surrogate for OS in higher-risk (HR) MDS pts who progressed on or after an HMA. Rigo is a Ras-mimetic that inhibits the RAS-RAF-MEK pathway, which is frequently activated in HR MDS (Athuluri-Divakar Cell 2016; Gil-Bazo Cancer Biol Ther 2016). Methods: Eligible MDS pts had 5-30% BMBL confirmed within 6 wks pre-study and progression per International Working Group (IWG) 2006 criteria on or after HMAs within 2 yrs. Rigo 1800 mg/24 hrs was continuously infused over 72 hrs q 2 wks × 8 cycles, then q 4 wks until progression or unacceptable toxicity. Prim..
View full abstract